Supplemental Table I.

Secondary outcomes: All cause mortality (death) and admission for heart failure: Doubling of Galectin 3

	Death (N = 164)		Hospitalizations due to Heart failure (N = 145)
Variable	Hazard Ratio (95% CI)	P-value	Hazard Ratio (95% CI)	P-value
Galectin 3 (doubling)	2.15 (1.67 – 2.76)	<0.0001	1.76 (1.36 – 2.28)	<0.0001
Adjusted for age (continuous), gender	2.01 (1.54 – 2.61)	<0.0001	1.70 (1.30 – 2.22)	<0.0001
Adjusted for age (continuous), gender, BNP	1.74 (1.32 – 2.29)	<0.0001	1.65 (1.26 – 2.18)	<0.0001
Adjusted for age (continuous), gender, BNP, eGFR	1.42 (1.02 – 1.96)	0.036	1.26 (0.91 – 1.74)	0.162
Adjusted for age (continuous), gender, BNP, eGFR, diabetes	1.38 (1.00 – 1.91)	0.051	1.19 (0.86 – 1.65)	0.282
Adjusted for age (continuous), gender, BNP, eGFR, diabetes, LVEF*	1.21 (0.83 – 1.80)	0.320	1.00 (0.66 – 1.51)	0.991
Interaction with LVEF**		0.636		0.047

^*continuous.

^**reduced LVEFLVEF (≤40%) versus preserved LVEF (>40%).